Discovery of Dihydrochalcone as Potential Lead for Alzheimer’s Disease: In Silico and In Vitro Study

By the virtual screening method we have screened out Dihydrochalcone as a top-lead for the Alzheimer’s disease using the database of about 32364 natural compounds. The binding affinity of this ligand to amyloid beta (A) fibril has been thoroughly studied by computer simulation and experiment. Using the Thioflavin T (ThT) assay we have obtained the inhibition constant IC50 M. This result is in good agreement with the estimation of the binding free energy obtained by the molecular mechanic-Poisson Boltzmann surface area method and all-atom simulation with the force field CHARMM 27 and water model TIP3P. Cell viability assays indicated that Dihydrochalcone could effectively reduce the cytotoxicity induced by A. Thus, both in silico and in vitro studies show that Dihydrochalcone is a potential drug for the Alzheimers disease.

[1]  Son Tung Ngo,et al.  Curcumin binds to Aβ1-40 peptides and fibrils stronger than ibuprofen and naproxen. , 2012, The journal of physical chemistry. B.

[2]  Hui‐Ming Yu,et al.  Folding stability of amyloid‐β 40 monomer is an important determinant of the nucleation kinetics in fibrillization , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Calvin Yu-Chian Chen,et al.  TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico , 2011, PloS one.

[4]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[5]  Tracy O'Connor,et al.  Protein aggregation diseases: pathogenicity and therapeutic perspectives , 2010, Nature Reviews Drug Discovery.

[6]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[7]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[8]  G. Bernardi,et al.  Dopamine Modulates Cholinergic Cortical Excitability in Alzheimer's Disease Patients , 2009, Neuropsychopharmacology.

[9]  JoAnne McLaurin,et al.  Small molecule inhibitors of Aβ‐aggregation and neurotoxicity , 2009 .

[10]  Mark S. Johnson,et al.  ShaEP: Molecular Overlay Based on Shape and Electrostatic Potential , 2009, J. Chem. Inf. Model..

[11]  G. Bernardi,et al.  l-dopa modulates motor cortex excitability in Alzheimer’s disease patients , 2008, Journal of Neural Transmission.

[12]  A. Ganesan.  The impact of natural products upon modern drug discovery. , 2008, Current opinion in chemical biology.

[13]  W. Klein,et al.  Salvianolic acid B inhibits Aβ fibril formation and disaggregates preformed fibrils and protects against Aβ-induced cytotoxicty , 2008, Neurochemistry International.

[14]  Carsten Kutzner,et al.  GROMACS 4:  Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. , 2008, Journal of chemical theory and computation.

[15]  W. Klein,et al.  Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. , 2008, Neurochemistry international.

[16]  J. Gestwicki,et al.  Structure–activity Relationships of Amyloid Beta‐aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility , 2007, Chemical biology & drug design.

[17]  Robert P. Sheridan,et al.  Comparison of Topological, Shape, and Docking Methods in Virtual Screening , 2007, J. Chem. Inf. Model..

[18]  D Thirumalai,et al.  Monomer adds to preformed structured oligomers of Aβ-peptides by a two-stage dock–lock mechanism , 2007, Proceedings of the National Academy of Sciences.

[19]  V. Srinivasan,et al.  Melatonin in Alzheimer's disease and other neurodegenerative disorders , 2006, Behavioral and Brain Functions.

[20]  R. Tycko,et al.  Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. , 2006, Biochemistry.

[21]  Prabha Garg,et al.  In Silico Prediction of Blood Brain Barrier Permeability: An Artificial Neural Network Model , 2006, J. Chem. Inf. Model..

[22]  R. Riek,et al.  3D structure of Alzheimer's amyloid-β(1–42) fibrils , 2005 .

[23]  D. Dupré,et al.  Bonding patterns in a strong 3c2e C-H...C hydrogen bond. , 2005, The journal of physical chemistry. A.

[24]  R. Riek,et al.  3D structure of Alzheimer's amyloid-beta(1-42) fibrils. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Adam Douglass,et al.  Mechanism of Prion Propagation: Amyloid Growth Occurs by Monomer Addition , 2004, PLoS biology.

[26]  Christopher A Lipinski,et al.  Chris Lipinski discusses life and chemistry after the Rule of Five. , 2003, Drug discovery today.

[27]  R. Leapman,et al.  A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Lashuel,et al.  New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. , 2002, The Journal of biological chemistry.

[29]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[30]  K. Nguyen,et al.  Poly-L-lysine dissolves fibrillar aggregation of the Alzheimer beta-amyloid peptide in vitro. , 2002, Biochemical and biophysical research communications.

[31]  E. Neria,et al.  Development of indole-3-propionic acid (OXIGON™) for alzheimer’s disease , 2002, Journal of Molecular Neuroscience.

[32]  I. Grundke‐Iqbal,et al.  Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[34]  D. E. Clark,et al.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.

[35]  D. E. Clark.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.

[36]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.

[37]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..

[38]  G. Desiraju.  The C-H×××O Hydrogen Bond: Structural Implications and Supramolecular Design , 1996 .

[39]  David S. Goodsell,et al.  Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4 , 1996, J. Comput. Aided Mol. Des..

[40]  Hans-Joachim Böhm,et al.  The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure , 1994, J. Comput. Aided Mol. Des..

[41]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[42]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[43]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[44]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[45]  R. Hockney,et al.  Quiet high resolution computer models of a plasma , 1974 .

[46]  D. Shanno.  Conditioning of Quasi-Newton Methods for Function Minimization , 1970 .

[47]  H. Edelhoch,et al.  Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.